Novartis AG (NYSE:NVS) has signed a definitive agreement to acquire all outstanding capital stock of US-based neurosciences firm Cadent Therapeutics for around $770 million. Novartis to pay $210 million upfront for the acquisition of Cadent Once the companies close...
